The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2016 | Topics in multiple myeloma discussed at ASCO 2016
Sagar Lonial, MD from the Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the session ‘Are We Ready for Personalized Therapy?’ in multiple myeloma (MM) held at the American Society of Oncology (ASCO) 2016 Annual Meeting in Chicago, IL. According to Prof Lonial, the focus was on the assessment of risk and disease status as well as new treatment options. Some of the topics covered were risk assessment using new genetics and genomics information, use of minimal residual disease (MRD) assessment through next-generation sequencing (NGS) or flow cytometry and the use of new drugs in the relapse setting.
